How Enclomiphene Affects Testosterone

The testosterone-raising effect of enclomiphene is entirely downstream of its LH-stimulating mechanism. By blocking pituitary estrogen receptors, enclomiphene increases LH secretion. Elevated LH binds Leydig cell LH/CG receptors, activating the steroidogenic cascade and increasing intratesticular and serum testosterone production. Because testosterone is produced endogenously, the HPG axis remains functionally intact: the negative feedback loop between testosterone and the hypothalamus/pituitary is preserved (although shifted to a higher set-point by the ongoing estrogen receptor blockade). This is the fundamental difference from exogenous testosterone: enclomiphene raises testosterone while maintaining active gonadotropin secretion and spermatogenesis.

In the Kaminetsky et al. (2013) phase 3 trial, enclomiphene 25 mg/day raised total testosterone to a mean of 450-520 ng/dL in hypogonadal men (baseline approximately 200-250 ng/dL), comparable to testosterone gel 1.62% two pumps daily. The key difference was that the testosterone gel group had FSH suppressed to near-zero (with associated sperm count suppression), while the enclomiphene group maintained FSH and sperm counts throughout. In the community setting, total testosterone rises of 100-300 ng/dL from baseline are typical, placing most responders in the low-normal to mid-normal range (300-600 ng/dL). Unlike exogenous testosterone, very high testosterone levels are uncommon with enclomiphene because the intact negative feedback loop limits how high the axis can be driven.

Check total testosterone, free testosterone, LH, and FSH at baseline and at 6-8 weeks after starting enclomiphene. Unlike exogenous TRT, SHBG does not change meaningfully with enclomiphene (no hepatic estrogenic agonism), so free testosterone tracks closely with total testosterone and does not require the correction calculations needed during clomiphene therapy. Retest at 3 months if dose changes are made. For long-term monitoring, annual labs are appropriate in stable patients.

If testosterone response is insufficient at 25 mg/day after 8 weeks, confirm LH is rising (if LH is not rising, the problem is axis suppression, not dose). If LH is rising but testosterone response is poor, consider Leydig cell dysfunction from prior prolonged AAS use, requiring a longer recovery period or referral to endocrinology. Estradiol should be monitored alongside testosterone: the rise in testosterone will increase aromatization, and some men develop estrogenic side effects without SHBG buffering the increase. If estradiol rises excessively with symptoms, dose reduction is preferable to AI addition.